ClinicalTrials.gg
WithdrawnNCT04306237Updated Nov 10, 2025

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

A Phase 2 interventional study of IMB-1018972 and Placebo oral tablet in Refractory Angina, sponsored by Imbria Pharmaceuticals, Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Imbria Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Coronavirus pandemic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies in Angina Pectoris with a site in United States — 13 open to participants now, 17 under way, 2 of them phase 3. Angina Pectoris · United States.

Enrollment
70th of 73
0 · median 124
Started
2020
with 3 others
Phase 2
15 of 113
1 open now
Registered
92nd of 113
by date

Among the 113 studies in Angina Pectoris with a site in United States, this one is the 70th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2020, is one of 15 in phase 2, and was the 92nd registered.

Angina Pectoris

454 studies on the registry are indexed under Angina Pectoris; 68 are open to participants now.

Browse Angina Pectoris studies →

Open to participants now

13 of the 113 studies in Angina Pectoris with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Angina Pectoris studies recruiting now, 35 (74%) set no upper age limit and 1 (2%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Angina Pectoris with a site in United States, or all of them as a file.
02

Study summary

The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.

03

Conditions studied

  • Refractory Angina

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is between the ages of 18 and 85 years, inclusive.
  2. Is capable of understanding the written , and providing signed, dated, and witnessed written informed consent.
  3. Has complied with and is willing to continue to comply with the specified procedures (eg, angina diary during screening) and complete specific follow-up evaluations.
  4. Has coronary artery disease confirmed by at least one of the following:

    • Documented prior MI, CABG surgery, or PCI -OR-
    • Angiography performed within the 24 months prior to Visit 1 confirming CAD (eg, evidence of ≥70% stenosis of at least one major coronary artery or diffuse CAD).
  5. Has evidence of stress induced ischemia documented by either:

    • Protocol-specified ETT demonstrating at least 0.5 mm exercise-induced ST segment depression with onset \<9 minutes on at least 1 of the screening ETTs -OR-
    • Prior evidence of stress-induced reversible perfusion defect in the last 24 months (without intervening revascularization) identified by at least one of the following:

      • Radionuclide imaging study
      • Echocardiographic imaging study
      • FFR \<0.8
      • IFR \<0.89
      • FFR CT \<0.8
      • CFR \<2.5
  6. Has a minimum 3 month history of exertional angina, including angina with a minimum frequency of 2 anginal episodes per week on average for the 2 weeks prior to enrolling in the study while on optimal guideline directed medical therapy for their angina.
  7. Is on optimal, dual agent, antianginal therapy for their angina for at least 1 month prior to the first screening ETT. Consistent with ACC/AHA and ESC Class I guideline directed medical therapy (GDMT), criteria for optimal therapy include treatment with both: (a) a beta-adrenergic blocking agent and treatment with (b) a calcium channel blocker OR a long-acting nitrate. If unacceptable side effects are intolerable and documented with a therapy listed in (a) or (b), treatment with only 1 antianginal medication is acceptable. Additionally, patients should be treated with short-acting nitrates per GDMT.
  8. Is currently not clinically indicated for coronary revascularization (ie, PCI or CABG) in the opinion of the principle investigator at the time of screening through 6 months after randomization.
  9. Has a CCS score of II, III or stabilized IV for 1 month prior to screening.
  10. Meets the following requirements after 2 screening modified Bruce protocol ETTs:

    a. Stopping the treadmill test due to angina on each test b. Total exercise duration must fall between 3 and 9 minutes on each test c. To document inducible myocardial ischemia: i. For those patients with interpretable ECGs, at least 0.5 mm exercise induced ST segment depression must occur with onset \<9 minutes on at least 1 of the screening ETTs.

    d. Difference in TED between the 2 qualifying ETTs must not exceed 20% of the longer test or 1 minute, whichever limit is smaller.

    e. Consideration of a third ETT may be discussed by the investigator with the study medical monitor, who may authorize the performance of a third ETT a minimum of 5 days and no more than 10 days after the second ETT

Exclusion criteria

Exclusion Criteria:

  1. If any of the following have occurred:

    • Use of TMZ anytime in prior history
    • In the prior 6 months:

      • Diagnosis of Class 3 or 4 (heart failure)
      • Hospitalization for heart failure
      • Coronary artery bypass graft surgery
      • Cardiac resynchronization therapy placement or adjustments to CRT parameters
      • Implantable cardioverter defibrillator or biventricular pacemaker placement
    • In the prior 3 months:

      • Hospitalization for a cardiovascular indication
      • Cerebral vascular accident
      • Percutaneous coronary intervention
    • In the prior 1 month:

      • Use of perhexiline or meldonium.
  2. Has a history of moderate to severe valvular heart disease defined as aortic stenosis (valve area \<1.5 cm2), aortic insufficiency, mitral stenosis (valve area \<1.5 cm2), or mitral valve regurgitation of grade 3 or worse.
  3. Has significant hepatic disease, with increased liver function tests such as total , , or alanine aminotransferase more than 2 times of at baseline (excluding patients with documented history of Gilbert syndrome).
  4. Has severe renal impairment (ie, \<30 mL/min at screening, measured using 4-variable modification of diet in renal disease equation).
  5. Has a history of Parkinson disease, Parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
  6. Has a history of vasospastic angina or microvascular angina.
  7. Has an exacerbating cause for angina (eg, anemia [ie, \<10 g/dL], uncontrolled hypertension [ie, BP ≥160/90 mmHg], hyperthyroid, or rapid AF [ie, AF with average rate >120 beats per minute]) at screening.
  8. Has long- and life-threatening LV arrhythmia.
  9. Has comorbidities limiting to less than 3 years.
  10. Is pregnant, planning pregnancy, or lactating.
  11. Has a history of alcohol abuse or drug addiction.
  12. Has a positive test for drugs (eg, opiates, methadone, cocaine, amphetamines [including ecstasy], or barbiturates) at screening.
  13. Has a positive test for , antibodies, or HIV1/2 antibodies at screening.
  14. Is participating in another research study.
  15. Is an employee or family member of the investigator or study site personnel.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    IMB-1018972

    Participants will receive IMB-1018972 (200 mg) MR tablets twice daily for 16 weeks

    Drug: IMB-1018972

  • Placebo comparator
    Placebo

    Participants will receive matching placebo tablets twice daily for 16 weeks

    Drug: Placebo oral tablet

Interventions

  • IMB-1018972 200 mg tablet for oral administration

  • DrugPlacebo oral tablet

    Matched placebo tablet for oral administration

06

What researchers measure

Primary outcomes

  1. Modified Bruce Protocol Treadmill ETT

    Change from baseline to Week 8 in total exercise duration (seconds)

    Time frame: 8 weeks

  2. Safety and Tolerability of IMB-1018972 in Patients with Refractory Angina

    Incidence of AEs, changes from baseline in physical examinations, vital signs, clinical laboratories, and ECG

    Time frame: 16 weeks

Secondary outcomes

  1. Assess the benefit of IMB-1018972 on patient report of angina symptoms employing an electronic diary

    Change from baseline per week in the incidence of angina symptoms

    Time frame: 16 weeks

  2. Assess the potential treatment benefit of IMB-1018972 on patient report of rescue NTG use employing an electronic diary

    Change from baseline in daily counts of NTG use

    Time frame: 16 weeks

  3. Assess the potential treatment benefit of IMB-1018972 on patient activity employing a wearable device

    Change from baseline in total daily activity at Week 16 (activity units)

    Time frame: 16 weeks

07

Study locations

1 site
  • Imbria Investigational Site
    Boston, Massachusetts 02110, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Feb 2025, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2020
First posted
Mar 12, 2020
StartActual
May 1, 2020
Primary completionEst.
Feb 2025
CompletionEst.
Apr 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04306237
Lead sponsor
Imbria Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
May 1, 2020
Primary completion
Feb 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Nov 10, 2025

Study contacts

Paul Chamberlin, MD
study director · Imbria Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ninerafaxstat

Start the discussion